dc.contributor
Institut Català de la Salut
dc.contributor
[Pascual J] Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Malaga, Spain. [Attard G] Urological Cancer Research, University College London, London, UK. [Bidard FC] Department of Medical Oncology, Institut Curie, Paris, France. University of Versailles Saint-Quentin-en-Yvelines (UVSQ)/Paris-Saclay University, Saint Cloud, France. [Curigliano G] Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy. Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy. [De Mattos-Arruda L] IrsiCaixa, Hospital Universitari Trias i Pujol, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. [Diehn M] Department of Radiation Oncology, Stanford University School of Medicine, Stanford, USA. [Seoane J] Preclinical and Translational Research Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. ICREA, CIBERONC, Barcelona, Spain. Medical School, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Pascual, Javier
dc.contributor.author
Attard, Gerhardt
dc.contributor.author
Bidard, François-Clement
dc.contributor.author
Diehn, Maximilian
dc.contributor.author
Seoane Suarez, Joan
dc.contributor.author
Curigliano, Giuseppe
dc.contributor.author
De Mattos-Arruda, Leticia
dc.date.accessioned
2025-10-25T05:39:08Z
dc.date.available
2025-10-25T05:39:08Z
dc.date.issued
2023-04-17T12:55:42Z
dc.date.issued
2023-04-17T12:55:42Z
dc.identifier
Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022 Aug;33(8):750–68.
dc.identifier
https://hdl.handle.net/11351/9356
dc.identifier
10.1016/j.annonc.2022.05.520
dc.identifier
000945386600003
dc.identifier.uri
http://hdl.handle.net/11351/9356
dc.description.abstract
Circulating tumour DNA (ctDNA); Liquid biopsy; Precision medicine
dc.description.abstract
DNA tumoral circulant (ctDNA); Biòpsia líquida; Medicina de precisió
dc.description.abstract
ADN tumoral circulante (ctDNA); Biopsia líquida; Medicina de precisión
dc.description.abstract
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society for Medical Oncology convened an expert working group to review the analytical and clinical validity and utility of ctDNA assays. For patients with advanced cancer, validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, and may be used in routine clinical practice, provided the limitations of the assays are taken into account. Tissue-based testing remains the preferred test for many cancer patients, due to limitations of ctDNA assays detecting fusion events and copy number changes, although ctDNA assays may be routinely used when faster results will be clinically important, or when tissue biopsies are not possible or inappropriate. Reflex tumour testing should be considered following a non-informative ctDNA result, due to false-negative results with ctDNA testing. In patients treated for early-stage cancers, detection of molecular residual disease or molecular relapse, has high evidence of clinical validity in anticipating future relapse in many cancers. Molecular residual disease/molecular relapse detection cannot be recommended in routine clinical practice, as currently there is no evidence for clinical utility in directing treatment. Additional potential applications of ctDNA assays, under research development and not recommended for routine practice, include identifying patients not responding to therapy with early dynamic changes in ctDNA levels, monitoring therapy for the development of resistance mutations before clinical progression, and in screening asymptomatic people for cancer. Recommendations for reporting of results, future development of ctDNA assays and future clinical research are made.
dc.description.abstract
This project was funded by the European Society for Medical Oncology (no grant number).
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Annals of Oncology;33(8)
dc.relation
https://doi.org/10.1016/j.annonc.2022.05.520
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Marcadors tumorals
dc.subject
Medicina personalitzada
dc.subject
CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Cell-Free Nucleic Acids::Circulating Tumor DNA
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine
dc.subject
DISEASES::Neoplasms
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::ácidos nucleicos::ácidos nucleicos libres de células::ADN tumoral circulante
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión
dc.subject
ENFERMEDADES::neoplasias
dc.title
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
